NCT02991456View on ClinicalTrials.gov

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

PHASE2CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

May 9, 2022

Study Completion Date

June 20, 2022

Conditions

Chemo-radiation Induced Nausea and Vomiting

Interventions

DRUG

Rolapitant

single 180 mg dose by mouth

DRUG

Ondansetron

8 mg by mouth daily

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT02991456 - Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide | Biotech Hunter | Biotech Hunter